TP53 and breast carcinoma: Studies of TP53 mutations in metastatic breast cancer lesions have been limited by the lack of availability of tissue, perhaps because of the infrequency of re-biopsy of radiologically detected suspicious lesions in patients with a previous history of primary breast cancer.